BioSpace News Archive

On 16 December, the world’s leading healthcare ecosystem platform, Ping An Healthcare and Technology Company Limited announced that the Company and Thailand’s largest healthcare group Bangkok Dusit Medical Services jointly launched the overseas video consultation service for second opinions.

Demonstrated rapid, durable, and statistically significant improvement in depressive symptoms as measured by MADRS total score compared to placebo (p=0.002 on primary endpoint)

An expert Work Group released a white paper outlining recommendations for the next iteration of the Centers for Medicare and Medicaid Services ' Oncology Care Model.

LTTS felicitated at 8th Foundation Day of Global Innovation & Technology Alliance

Humana Inc. (NYSE: HUM) today announced it has signed a definitive agreement to acquire privately held Enclara Healthcare (Enclara), one of the nation’s largest hospice pharmacy and benefit management providers, from Consonance Capital Partners and Enclara management.

In an update released today by CENTOGENE (Nasdaq: CNTG) to CentoMD® - the Company’s data repository of epidemiologic, phenotypic, and clinical data, - since September 2019 the number of analyzed cases has grown by 11% to more than 400,000, and the number of total variants has increased to 12.2 million from across 120 countries.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation (ODD) for RYANODEX® (dantrolene sodium) for the treatment of organophosphate exposure.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal year ended September 30, 2019.

LHC Group, Inc. (NASDAQ: LHCG) and Medalogix, the leading provider of data science in home health, announced a further expansion of their partnership with the implementation of Medalogix Bridge in multiple markets.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced its decision to discontinue development of suvodirsen for patients with Duchenne muscular dystrophy (DMD) who have mutations amenable to exon 51 skipping, based on its interim analysis of the Phase 1 open-label extension (OLE) study.